Bombed-out listed drugmaker Mayne Pharma is in the firing line of activist investor Viburnum Funds, which is taking the board to task after the drug manufacturer sliced its $113 million capital return program by 30 per cent.
Viburnum Funds managing partner Craig Coleman. Philip Gostelow
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com
